Literature references that cite this PDB file's
key reference
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
M.Zakrzewska,
A.Wiedlocha,
A.Szlachcic,
D.Krowarsch,
J.Otlewski,
and
S.Olsnes
(2009).
Increased protein stability of FGF1 can compensate for its reduced affinity for heparin.
|
| |
J Biol Chem, 284,
25388-25403.
|
 |
|
|
|
|
 |
K.Tan,
M.Duquette,
J.H.Liu,
K.Shanmugasundaram,
A.Joachimiak,
J.T.Gallagher,
A.C.Rigby,
J.H.Wang,
and
J.Lawler
(2008).
Heparin-induced cis- and trans-dimerization modes of the thrombospondin-1 N-terminal domain.
|
| |
J Biol Chem, 283,
3932-3941.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
N.S.Gandhi,
and
R.L.Mancera
(2008).
The structure of glycosaminoglycans and their interactions with proteins.
|
| |
Chem Biol Drug Des, 72,
455-482.
|
 |
|
|
|
|
 |
S.J.Goodger,
C.J.Robinson,
K.J.Murphy,
N.Gasiunas,
N.J.Harmer,
T.L.Blundell,
D.A.Pye,
and
J.T.Gallagher
(2008).
Evidence that heparin saccharides promote FGF2 mitogenesis through two distinct mechanisms.
|
| |
J Biol Chem, 283,
13001-13008.
|
 |
|
|
|
|
 |
C.L.Chaffer,
B.Dopheide,
P.Savagner,
E.W.Thompson,
and
E.D.Williams
(2007).
Aberrant fibroblast growth factor receptor signaling in bladder and other cancers.
|
| |
Differentiation, 75,
831-842.
|
 |
|
|
|
|
 |
C.W.Vander Kooi,
M.A.Jusino,
B.Perman,
D.B.Neau,
H.D.Bellamy,
and
D.J.Leahy
(2007).
Structural basis for ligand and heparin binding to neuropilin B domains.
|
| |
Proc Natl Acad Sci U S A, 104,
6152-6157.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
H.Fan,
H.Li,
M.Zhang,
and
C.R.Middaugh
(2007).
Effects of solutes on empirical phase diagrams of human fibroblast growth factor 1.
|
| |
J Pharm Sci, 96,
1490-1503.
|
 |
|
|
|
|
 |
N.Kulahin,
V.Kiselyov,
A.Kochoyan,
O.Kristensen,
J.S.Kastrup,
V.Berezin,
E.Bock,
and
M.Gajhede
(2007).
Structure of rat acidic fibroblast growth factor at 1.4 A resolution.
|
| |
Acta Crystallogr Sect F Struct Biol Cryst Commun, 63,
65-68.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
A.Canales,
R.Lozano,
B.López-Méndez,
J.Angulo,
R.Ojeda,
P.M.Nieto,
M.Martín-Lomas,
G.Giménez-Gallego,
and
J.Jiménez-Barbero
(2006).
Solution NMR structure of a human FGF-1 monomer, activated by a hexasaccharide heparin-analogue.
|
| |
FEBS J, 273,
4716-4727.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
A.Canales-Mayordomo,
R.Fayos,
J.Angulo,
R.Ojeda,
M.Martín-Pastor,
P.M.Nieto,
M.Martín-Lomas,
R.Lozano,
G.Giménez-Gallego,
and
J.Jiménez-Barbero
(2006).
Backbone dynamics of a biologically active human FGF-1 monomer, complexed to a hexasaccharide heparin-analogue, by 15N NMR relaxation methods.
|
| |
J Biomol NMR, 35,
225-239.
|
 |
|
|
|
|
 |
C.J.Robinson,
B.Mulloy,
J.T.Gallagher,
and
S.E.Stringer
(2006).
VEGF165-binding sites within heparan sulfate encompass two highly sulfated domains and can be liberated by K5 lyase.
|
| |
J Biol Chem, 281,
1731-1740.
|
 |
|
|
|
|
 |
H.Jenssen,
P.Hamill,
and
R.E.Hancock
(2006).
Peptide antimicrobial agents.
|
| |
Clin Microbiol Rev, 19,
491-511.
|
 |
|
|
|
|
 |
J.Kittiworakarn,
A.Lecoq,
G.Moine,
R.Thai,
E.Lajeunesse,
P.Drevet,
C.Vidaud,
A.Ménez,
and
M.Léonetti
(2006).
HIV-1 Tat raises an adjuvant-free humoral immune response controlled by its core region and its ability to form cysteine-mediated oligomers.
|
| |
J Biol Chem, 281,
3105-3115.
|
 |
|
|
|
|
 |
R.Sasisekharan,
R.Raman,
and
V.Prabhakar
(2006).
Glycomics approach to structure-function relationships of glycosaminoglycans.
|
| |
Annu Rev Biomed Eng, 8,
181-231.
|
 |
|
|
|
|
 |
A.Naggi,
B.Casu,
M.Perez,
G.Torri,
G.Cassinelli,
S.Penco,
C.Pisano,
G.Giannini,
R.Ishai-Michaeli,
and
I.Vlodavsky
(2005).
Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol splitting.
|
| |
J Biol Chem, 280,
12103-12113.
|
 |
|
|
|
|
 |
C.J.Robinson,
N.J.Harmer,
S.J.Goodger,
T.L.Blundell,
and
J.T.Gallagher
(2005).
Cooperative dimerization of fibroblast growth factor 1 (FGF1) upon a single heparin saccharide may drive the formation of 2:2:1 FGF1.FGFR2c.heparin ternary complexes.
|
| |
J Biol Chem, 280,
42274-42282.
|
 |
|
|
|
|
 |
J.P.Li,
M.L.Galvis,
F.Gong,
X.Zhang,
E.Zcharia,
S.Metzger,
I.Vlodavsky,
R.Kisilevsky,
and
U.Lindahl
(2005).
In vivo fragmentation of heparan sulfate by heparanase overexpression renders mice resistant to amyloid protein A amyloidosis.
|
| |
Proc Natl Acad Sci U S A, 102,
6473-6477.
|
 |
|
|
|
|
 |
L.Jin,
P.E.Barran,
J.A.Deakin,
M.Lyon,
and
D.Uhrín
(2005).
Conformation of glycosaminoglycans by ion mobility mass spectrometry and molecular modelling.
|
| |
Phys Chem Chem Phys, 7,
3464-3471.
|
 |
|
|
|
|
 |
T.C.Aupérin,
G.R.Bolduc,
M.J.Baron,
A.Heroux,
D.J.Filman,
L.C.Madoff,
and
J.M.Hogle
(2005).
Crystal structure of the N-terminal domain of the group B streptococcus alpha C protein.
|
| |
J Biol Chem, 280,
18245-18252.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
M.J.Bernett,
T.Somasundaram,
and
M.Blaber
(2004).
An atomic resolution structure for human fibroblast growth factor 1.
|
| |
Proteins, 57,
626-634.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
S.Ashikari-Hada,
H.Habuchi,
Y.Kariya,
N.Itoh,
A.H.Reddi,
and
K.Kimata
(2004).
Characterization of growth factor-binding structures in heparin/heparan sulfate using an octasaccharide library.
|
| |
J Biol Chem, 279,
12346-12354.
|
 |
|
|
|
|
 |
A.Facchiano,
K.Russo,
A.M.Facchiano,
F.De Marchis,
F.Facchiano,
D.Ribatti,
M.S.Aguzzi,
and
M.C.Capogrossi
(2003).
Identification of a novel domain of fibroblast growth factor 2 controlling its angiogenic properties.
|
| |
J Biol Chem, 278,
8751-8760.
|
 |
|
|
|
|
 |
C.Birchmeier,
W.Birchmeier,
E.Gherardi,
and
G.F.Vande Woude
(2003).
Met, metastasis, motility and more.
|
| |
Nat Rev Mol Cell Biol, 4,
915-925.
|
 |
|
|
|
|
 |
C.Fernández-Tornero,
R.M.Lozano,
M.Redondo-Horcajo,
A.M.Gómez,
J.C.López,
E.Quesada,
C.Uriel,
S.Valverde,
P.Cuevas,
A.Romero,
and
G.Giménez-Gallego
(2003).
Leads for development of new naphthalenesulfonate derivatives with enhanced antiangiogenic activity: crystal structure of acidic fibroblast growth factor in complex with 5-amino-2-naphthalene sulfonate.
|
| |
J Biol Chem, 278,
21774-21781.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
K.D.Kent,
and
J.A.Bomser
(2003).
Bovine pituitary extract provides remarkable protection against oxidative stress in human prostate epithelial cells.
|
| |
In Vitro Cell Dev Biol Anim, 39,
388-394.
|
 |
|
|
|
|
 |
R.Raman,
G.Venkataraman,
S.Ernst,
V.Sasisekharan,
and
R.Sasisekharan
(2003).
Structural specificity of heparin binding in the fibroblast growth factor family of proteins.
|
| |
Proc Natl Acad Sci U S A, 100,
2357-2362.
|
 |
|
|
|
|
 |
T.S.Udayakumar,
E.L.Bair,
R.B.Nagle,
and
G.T.Bowden
(2003).
Pharmacological inhibition of FGF receptor signaling inhibits LNCaP prostate tumor growth, promatrilysin, and PSA expression.
|
| |
Mol Carcinog, 38,
70-77.
|
 |
|
|
|
|
 |
Y.Luo,
H.H.Cho,
and
W.L.McKeehan
(2003).
Biospecific extraction and neutralization of anticoagulant heparin with fibroblast growth factors (FGF).
|
| |
J Pharm Sci, 92,
2117-2127.
|
 |
|
|
|
|
 |
Z.L.Wu,
L.Zhang,
T.Yabe,
B.Kuberan,
D.L.Beeler,
A.Love,
and
R.D.Rosenberg
(2003).
The involvement of heparan sulfate (HS) in FGF1/HS/FGFR1 signaling complex.
|
| |
J Biol Chem, 278,
17121-17129.
|
 |
|
|
|
|
 |
A.I.Arunkumar,
S.Srisailam,
T.K.Kumar,
K.M.Kathir,
Y.H.Chi,
H.M.Wang,
G.G.Chang,
I.Chiu,
and
C.Yu
(2002).
Structure and stability of an acidic fibroblast growth factor from Notophthalmus viridescens.
|
| |
J Biol Chem, 277,
46424-46432.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
A.I.Arunkumar,
T.K.Kumar,
K.M.Kathir,
S.Srisailam,
H.M.Wang,
P.S.Leena,
Y.H.Chi,
H.C.Chen,
C.H.Wu,
R.T.Wu,
G.G.Chang,
I.M.Chiu,
and
C.Yu
(2002).
Oligomerization of acidic fibroblast growth factor is not a prerequisite for its cell proliferation activity.
|
| |
Protein Sci, 11,
1050-1061.
|
 |
|
|
|
|
 |
B.K.Yeh,
A.V.Eliseenkova,
A.N.Plotnikov,
D.Green,
J.Pinnell,
T.Polat,
A.Gritli-Linde,
R.J.Linhardt,
and
M.Mohammadi
(2002).
Structural basis for activation of fibroblast growth factor signaling by sucrose octasulfate.
|
| |
Mol Cell Biol, 22,
7184-7192.
|
 |
|
|
|
|
 |
D.Letourneur,
D.Machy,
A.Pellé,
E.Marcon-Bachari,
G.D'Angelo,
M.Vogel,
F.Chaubet,
and
J.B.Michel
(2002).
Heparin and non-heparin-like dextrans differentially modulate endothelial cell proliferation: in vitro evaluation with soluble and crosslinked polysaccharide matrices.
|
| |
J Biomed Mater Res, 60,
94.
|
 |
|
|
|
|
 |
D.McCabe,
T.Cukierman,
and
J.E.Gabay
(2002).
Basic residues in azurocidin/HBP contribute to both heparin binding and antimicrobial activity.
|
| |
J Biol Chem, 277,
27477-27488.
|
 |
|
|
|
|
 |
I.Capila,
and
R.J.Linhardt
(2002).
Heparin-protein interactions.
|
| |
Angew Chem Int Ed Engl, 41,
391-412.
|
 |
|
|
|
|
 |
J.Kim,
S.I.Blaber,
and
M.Blaber
(2002).
Alternative type I and I' turn conformations in the beta8/beta9 beta-hairpin of human acidic fibroblast growth factor.
|
| |
Protein Sci, 11,
459-466.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
J.Kreuger,
T.Matsumoto,
M.Vanwildemeersch,
T.Sasaki,
R.Timpl,
L.Claesson-Welsh,
D.Spillmann,
and
U.Lindahl
(2002).
Role of heparan sulfate domain organization in endostatin inhibition of endothelial cell function.
|
| |
EMBO J, 21,
6303-6311.
|
 |
|
|
|
|
 |
J.M.Trowbridge,
J.A.Rudisill,
D.Ron,
and
R.L.Gallo
(2002).
Dermatan sulfate binds and potentiates activity of keratinocyte growth factor (FGF-7).
|
| |
J Biol Chem, 277,
42815-42820.
|
 |
|
|
|
|
 |
K.Honke,
and
N.Taniguchi
(2002).
Sulfotransferases and sulfated oligosaccharides.
|
| |
Med Res Rev, 22,
637-654.
|
 |
|
|
|
|
 |
M.Zamai,
C.Hariharan,
D.Pines,
M.Safran,
A.Yayon,
V.R.Caiolfa,
R.Cohen-Luria,
E.Pines,
and
A.H.Parola
(2002).
Nature of Interaction between basic fibroblast growth factor and the antiangiogenic drug 7,7-(carbonyl-bis[imino-N-methyl-4,2-pyrrolecarbonylimino[N-methyl-4,2-pyrrole]-carbonylimino])-bis-(1,3-naphtalene disulfonate). II. Removal of polar interactions affects protein folding.
|
| |
Biophys J, 82,
2652-2664.
|
 |
|
|
|
|
 |
P.Stenlund,
M.J.Lindberg,
and
L.A.Tibell
(2002).
Structural requirements for high-affinity heparin binding: alanine scanning analysis of charged residues in the C-terminal domain of human extracellular superoxide dismutase.
|
| |
Biochemistry, 41,
3168-3175.
|
 |
|
|
|
|
 |
R.Sasisekharan,
Z.Shriver,
G.Venkataraman,
and
U.Narayanasami
(2002).
Roles of heparan-sulphate glycosaminoglycans in cancer.
|
| |
Nat Rev Cancer, 2,
521-528.
|
 |
|
|
|
|
 |
S.M.Prince,
M.Achtman,
and
J.P.Derrick
(2002).
Crystal structure of the OpcA integral membrane adhesin from Neisseria meningitidis.
|
| |
Proc Natl Acad Sci U S A, 99,
3417-3421.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
Sachchidanand,
O.Lequin,
D.Staunton,
B.Mulloy,
M.J.Forster,
K.Yoshida,
and
I.D.Campbell
(2002).
Mapping the heparin-binding site on the 13-14F3 fragment of fibronectin.
|
| |
J Biol Chem, 277,
50629-50635.
|
 |
|
|
|
|
 |
C.P.Libeu,
S.Lund-Katz,
M.C.Phillips,
S.Wehrli,
M.J.Hernáiz,
I.Capila,
R.J.Linhardt,
R.L.Raffaï,
Y.M.Newhouse,
F.Zhou,
and
K.H.Weisgraber
(2001).
New insights into the heparan sulfate proteoglycan-binding activity of apolipoprotein E.
|
| |
J Biol Chem, 276,
39138-39144.
|
 |
|
|
|
|
 |
D.Lietha,
D.Y.Chirgadze,
B.Mulloy,
T.L.Blundell,
and
E.Gherardi
(2001).
Crystal structures of NK1-heparin complexes reveal the basis for NK1 activity and enable engineering of potent agonists of the MET receptor.
|
| |
EMBO J, 20,
5543-5555.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
H.J.Hecht,
R.Adar,
B.Hofmann,
O.Bogin,
H.Weich,
and
A.Yayon
(2001).
Structure of fibroblast growth factor 9 shows a symmetric dimer with unique receptor- and heparin-binding interfaces.
|
| |
Acta Crystallogr D Biol Crystallogr, 57,
378-384.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
L.Martin,
C.Blanpain,
P.Garnier,
V.Wittamer,
M.Parmentier,
and
C.Vita
(2001).
Structural and functional analysis of the RANTES-glycosaminoglycans interactions.
|
| |
Biochemistry, 40,
6303-6318.
|
 |
|
|
|
|
 |
S.Ye,
Y.Luo,
W.Lu,
R.B.Jones,
R.J.Linhardt,
I.Capila,
T.Toida,
M.Kan,
H.Pelletier,
and
W.L.McKeehan
(2001).
Structural basis for interaction of FGF-1, FGF-2, and FGF-7 with different heparan sulfate motifs.
|
| |
Biochemistry, 40,
14429-14439.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
W.Shao,
E.Fernandez,
A.Sachpatzidis,
J.Wilken,
D.A.Thompson,
B.I.Schweitzer,
and
E.Lolis
(2001).
CCR2 and CCR5 receptor-binding properties of herpesvirus-8 vMIP-II based on sequence analysis and its solution structure.
|
| |
Eur J Biochem, 268,
2948-2959.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
A.Yoneda,
M.Asada,
Y.Oda,
M.Suzuki,
and
T.Imamura
(2000).
Engineering of an FGF-proteoglycan fusion protein with heparin-independent, mitogenic activity.
|
| |
Nat Biotechnol, 18,
641-644.
|
 |
|
|
|
|
 |
D.J.Stauber,
A.D.DiGabriele,
and
W.A.Hendrickson
(2000).
Structural interactions of fibroblast growth factor receptor with its ligands.
|
| |
Proc Natl Acad Sci U S A, 97,
49-54.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
D.M.Ornitz
(2000).
FGFs, heparan sulfate and FGFRs: complex interactions essential for development.
|
| |
Bioessays, 22,
108-112.
|
 |
|
|
|
|
 |
H.Habuchi,
M.Tanaka,
O.Habuchi,
K.Yoshida,
H.Suzuki,
K.Ban,
and
K.Kimata
(2000).
The occurrence of three isoforms of heparan sulfate 6-O-sulfotransferase having different specificities for hexuronic acid adjacent to the targeted N-sulfoglucosamine.
|
| |
J Biol Chem, 275,
2859-2868.
|
 |
|
|
|
|
 |
M.Guzmán-Casado,
J.M.Sánchez-Ruiz,
M.El Harrous,
G.Giménez-Gallego,
and
A.Parody-Morreale
(2000).
Energetics of myo-inositol hexasulfate binding to human acidic fibroblast growth factor effect of ionic strength and temperature.
|
| |
Eur J Biochem, 267,
3477-3486.
|
 |
|
|
|
|
 |
M.L.Tyan
(2000).
Effects of inositol, LiCl, and heparin on the antibody responses to SRBC by normal and immunodeficient XID mice.
|
| |
Proc Soc Exp Biol Med, 224,
187-190.
|
 |
|
|
|
|
 |
M.Lyon,
G.Rushton,
J.A.Askari,
M.J.Humphries,
and
J.T.Gallagher
(2000).
Elucidation of the structural features of heparan sulfate important for interaction with the Hep-2 domain of fibronectin.
|
| |
J Biol Chem, 275,
4599-4606.
|
 |
|
|
|
|
 |
R.L.Gallo
(2000).
Proteoglycans and cutaneous vascular defense and repair.
|
| |
J Investig Dermatol Symp Proc, 5,
55-60.
|
 |
|
|
|
|
 |
R.van der Voort,
R.M.Keehnen,
E.A.Beuling,
M.Spaargaren,
and
S.T.Pals
(2000).
Regulation of cytokine signaling by B cell antigen receptor and CD40-controlled expression of heparan sulfate proteoglycans.
|
| |
J Exp Med, 192,
1115-1124.
|
 |
|
|
|
|
 |
T.L.Blundell,
D.F.Burke,
D.Chirgadze,
V.Dhanaraj,
M.Hyvönen,
C.A.Innis,
E.Parisini,
L.Pellegrini,
M.Sayed,
and
B.L.Sibanda
(2000).
Protein-protein interactions in receptor activation and intracellular signalling.
|
| |
Biol Chem, 381,
955-959.
|
 |
|
|
|
|
 |
Y.Liu,
A.J.Chirino,
Z.Misulovin,
C.Leteux,
T.Feizi,
M.C.Nussenzweig,
and
P.J.Bjorkman
(2000).
Crystal structure of the cysteine-rich domain of mannose receptor complexed with a sulfated carbohydrate ligand.
|
| |
J Exp Med, 191,
1105-1116.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
A.Sharma,
J.A.Askari,
M.J.Humphries,
E.Y.Jones,
and
D.I.Stuart
(1999).
Crystal structure of a heparin- and integrin-binding segment of human fibronectin.
|
| |
EMBO J, 18,
1468-1479.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
A.Wettreich,
A.Sebollela,
M.A.Carvalho,
S.P.Azevedo,
R.Borojevic,
S.T.Ferreira,
and
T.Coelho-Sampaio
(1999).
Acidic pH modulates the interaction between human granulocyte-macrophage colony-stimulating factor and glycosaminoglycans.
|
| |
J Biol Chem, 274,
31468-31475.
|
 |
|
|
|
|
 |
B.Berman,
O.Ostrovsky,
M.Shlissel,
T.Lang,
D.Regan,
I.Vlodavsky,
R.Ishai-Michaeli,
and
D.Ron
(1999).
Similarities and differences between the effects of heparin and glypican-1 on the bioactivity of acidic fibroblast growth factor and the keratinocyte growth factor.
|
| |
J Biol Chem, 274,
36132-36138.
|
 |
|
|
|
|
 |
D.Mikhailov,
H.C.Young,
R.J.Linhardt,
and
K.H.Mayo
(1999).
Heparin dodecasaccharide binding to platelet factor-4 and growth-related protein-alpha. Induction of a partially folded state and implications for heparin-induced thrombocytopenia.
|
| |
J Biol Chem, 274,
25317-25329.
|
 |
|
|
|
|
 |
E.Hurt-Camejo,
B.Rosengren,
P.Sartipy,
K.Elfsberg,
G.Camejo,
and
L.Svensson
(1999).
CD44, a cell surface chondroitin sulfate proteoglycan, mediates binding of interferon-gamma and some of its biological effects on human vascular smooth muscle cells.
|
| |
J Biol Chem, 274,
18957-18964.
|
 |
|
|
|
|
 |
F.Lustig,
J.Hoebeke,
C.Simonson,
G.Ostergren-Lundén,
G.Bondjers,
U.Rüetchi,
and
G.Fager
(1999).
Processing of PDGF gene products determines interactions with glycosaminoglycans.
|
| |
J Mol Recognit, 12,
112-120.
|
 |
|
|
|
|
 |
G.Venkataraman,
R.Raman,
V.Sasisekharan,
and
R.Sasisekharan
(1999).
Molecular characteristics of fibroblast growth factor-fibroblast growth factor receptor-heparin-like glycosaminoglycan complex.
|
| |
Proc Natl Acad Sci U S A, 96,
3658-3663.
|
 |
|
|
|
|
 |
G.Venkataraman,
Z.Shriver,
J.C.Davis,
and
R.Sasisekharan
(1999).
Fibroblast growth factors 1 and 2 are distinct in oligomerization in the presence of heparin-like glycosaminoglycans.
|
| |
Proc Natl Acad Sci U S A, 96,
1892-1897.
|
 |
|
|
|
|
 |
L.Citores,
J.Wesche,
E.Kolpakova,
and
S.Olsnes
(1999).
Uptake and intracellular transport of acidic fibroblast growth factor: evidence for free and cytoskeleton-anchored fibroblast growth factor receptors.
|
| |
Mol Biol Cell, 10,
3835-3848.
|
 |
|
|
|
|
 |
M.Kan,
X.Wu,
F.Wang,
and
W.L.McKeehan
(1999).
Specificity for fibroblast growth factors determined by heparan sulfate in a binary complex with the receptor kinase.
|
| |
J Biol Chem, 274,
15947-15952.
|
 |
|
|
|
|
 |
R.D.Klein,
M.S.Maliner-Jongewaard,
T.S.Udayakumar,
J.L.Boyd,
R.B.Nagle,
and
G.T.Bowden
(1999).
Promatrilysin expression is induced by fibroblast growth factors in the prostatic carcinoma cell line LNCaP but not in normal primary prostate epithelial cells.
|
| |
Prostate, 41,
215-223.
|
 |
|
|
|
|
 |
R.van der Voort,
T.E.Taher,
V.J.Wielenga,
M.Spaargaren,
R.Prevo,
L.Smit,
G.David,
G.Hartmann,
E.Gherardi,
and
S.T.Pals
(1999).
Heparan sulfate-modified CD44 promotes hepatocyte growth factor/scatter factor-induced signal transduction through the receptor tyrosine kinase c-Met.
|
| |
J Biol Chem, 274,
6499-6506.
|
 |
|
|
|
|
 |
S.Vallés,
C.Tsoi,
W.Y.Huang,
D.Wyllie,
F.Carlotti,
J.A.Askari,
M.J.Humphries,
S.K.Dower,
and
E.E.Qwarnström
(1999).
Recruitment of a heparan sulfate subunit to the interleukin-1 receptor complex. Regulation by fibronectin attachment.
|
| |
J Biol Chem, 274,
20103-20109.
|
 |
|
|
|
|
 |
T.Sasaki,
H.Larsson,
J.Kreuger,
M.Salmivirta,
L.Claesson-Welsh,
U.Lindahl,
E.Hohenester,
and
R.Timpl
(1999).
Structural basis and potential role of heparin/heparan sulfate binding to the angiogenesis inhibitor endostatin.
|
| |
EMBO J, 18,
6240-6248.
|
 |
|
|
|
|
 |
W.L.McKeehan,
X.Wu,
and
M.Kan
(1999).
Requirement for anticoagulant heparan sulfate in the fibroblast growth factor receptor complex.
|
| |
J Biol Chem, 274,
21511-21514.
|
 |
|
|
|
|
 |
Y.Kakuta,
T.Sueyoshi,
M.Negishi,
and
L.C.Pedersen
(1999).
Crystal structure of the sulfotransferase domain of human heparan sulfate N-deacetylase/ N-sulfotransferase 1.
|
| |
J Biol Chem, 274,
10673-10676.
|
 |
|
PDB code:
|
 |
|
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|